Lipid nanoparticles (LNPs) have emerged as a leading platform for nucleic acid delivery; however, their inherent tendency to accumulate in the liver continues to limit broader therapeutic applications ...

RNA vaccines represent a transformative advance in vaccinology, combining rapid development timelines, scalable manufacturing ...

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints.

By Sneha S K June 30 (Reuters) - The U.S. Food and Drug Administration's staff reviewers said available evidence does not ...

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth ...

USP’s Diane McCarthy on the emerging standards platform and opportunities for stakeholders to help shape standards evolution.

The health secretary has advocated for deregulating more peptides, but FDA scientists point to a lack of data about their ...

Replimune Group, Inc. nears a pivotal FDA AdCom for RP1 ahead of an Aug 2, 2026 decision. Click for this REPLY stock update ...

Immunomic Therapeutics begins patient dosing in phase 1 trial of ITI-9001 to treat Japanese cedar pollen allergy: Rockville, Maryland Immunom ...

FDA decision expected by August 2, 2026WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel ...

Immunomic Therapeutics Inc. (ITI), a clinical-stage biotechnology company and a subsidiary of HLB, today announced that the first participant has been dosed in the Phase 1 clinical trial of ITI-9001, ...

As genome editing therapies move through clinical trials to regulatory approval, scientists continue the quest for the holy ...